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The past ten years of research have identiﬁed a number of key roles for glycogen synthase kinase 3 (GSK3) at the synapse. In terms
of presynaptic physiology, critical roles for GSK3 have been revealed in the growth and maturation of the nerve terminal and more
recently a key role in the control of activity-dependent bulk endocytosis of synaptic vesicles. This paper will summarise the major
roles assigned to GSK3 in both immature and mature nerve terminals, the substrates GSK3 phosphorylates to exert its action, and
how GSK3 activity is regulated by diﬀerent presynaptic signalling cascades. The number of essential roles for GSK3, coupled with
the numerous signalling cascades all converging to regulate its activity, suggests that GSK3 is a key integrator of multiple inputs
to modulate the strength of neurotransmission. Modulation of these pathways may point to potential mechanisms to overcome
synaptic failure in neurodegenerative disorders such as Alzheimer’s disease.
1.Introduction
Glycogen synthase kinase 3 (GSK3) is a serine/threonine
kinase that was originally identiﬁed as a regulator of cell
metabolism but has a variety of roles in cellular function
including cell survival, proliferation, neural development,
and neurotransmission [1, 2]. GSK3 exists as two isoforms
encoded by separate genes: GSK3α (51kDa) and GSK3β
(47kDa) [3]. Both isoforms are ubiquitously expressed
and, although structurally similar, perform overlapping but
nonidentical functions [3]. GSK3 is constitutively active in
most cells and is negatively regulated by phosphorylation
a ti t sN - t e r m i n u s( S e r - 2 1f o rG S K 3 α and Ser-9 for GSK3β)
by a variety of upstream signalling cascades [4]. GSK3 is
an unusual kinase in that it generally only phosphorylates a
substrate after a previous phosphorylation of the substrate
by another protein kinase, an event called “priming” [1, 3].
G S K 3h a sb e e ni m p l i c a t e di ns e v e r a ln e u r o n a ld i s o r d e r ss u c h
as schizophrenia, bipolar disorder, and Alzheimer’s disease
[4, 5].
A number of the disorders mentioned above are part of
a growing list of diseases called synaptopathies that have at
their core a defect in synaptic communication [6]. GSK3 is
expressed at the synapse and is found in both immature and
mature nerve terminals (presynapses) [7–10]. This localisa-
tion suggested a role for GSK3 in presynaptic function and
over the past 10 years this has been revealed, ranging from
axonal growth and synaptogenesis to regulation of synaptic
vesicle (SV) recycling in the mature synapse. This paper will
summarise these studies and place the function of GSK3 in
the context of nerve terminal physiology.
2. GSK3FunctioninImmatureNerveTerminals
2.1. GSK3 Role in Axonal Growth and Polarity. GSK3 sig-
nalling is essential for multiple aspects of synaptogenesis: the
formation of a functional synapse from nascent neurites. For
the purposes of this paper, only the presynaptic contribution
ofGSK3insynaptogenesiswillbeconsidered;howeverGSK3
alsohasmultiplepostsynapticroles(forreviewssee[11,12]).
One of the ﬁrst elements of synaptogenesis is axonal
growth. There is an essential requirement for GSK3 activity
inthisprocess,withnumerousstudiesdemonstratingthatan
inhibition of GSK3 function greatly reduces axon elongation
[13–15]. In addition to controlling growth, GSK3 has a
key role in establishing neuronal polarity, speciﬁcally the
diﬀerentiation of immature neurites into nascent axons.
Inactive GSK3β (phosphorylated at Ser9) is localised at the2 International Journal of Alzheimer’s Disease
tip of all immature neurites before polarization; however,
once polarization is triggered, it is restricted to only the
single axonal tip [7, 13, 16]. Thus the localised inactiva-
tion of GSK3 seems to be critical for axonal polarity to
occur. In agreement, inhibition of GSK3 function using
pharmacological antagonists, peptide inhibitors or siRNA all
induced the formation of multiple axons [7, 15, 16], whereas
overexpression of a constitutively active GSK3β mutant
(Ser9Ala) inhibited axon formation in primary neuronal
culture [7, 16].
The control of localised microtubule dynamics is critical
forneuronal polarization [17], and a number of downstream
GSK3 substrates have microtubule organising activity. Col-
lapsin response mediator protein 2 (CRMP2) promotes
microtubule polymerization and when overexpressed in
neurons produced multiple axons [18, 19]. Also, adenoma-
tous polyposis coli (APC) protein stabilises microtubules
in its nonphosphorylated form and is enriched in the
nascent axon [20, 21]. GSK3 phosphorylates both CRMP2
and APC in vitro [16, 20, 22] and inhibition of GSK3
blocks CRMP2 phosphorylation in polarized axonal tips in
culture [16]. Furthermore a non-phosphorylatable mutant
of CRMP2 does not promote axon elongation but induces
multipleaxonswhenoverexpressedinneurons[16,22].Thus
phosphorylation of either CRMP2 or APC by GSK3 inhibits
their binding to microtubules [16, 20]. This promotes
microtubule polymerization, thus promoting growth and
preventing axonal polarization.
The control of GSK3 activity in both axonal growth
and polarization is regulated by an array of diﬀerent
growth factors. Classically, GSK3 is negatively regulated
via downstream signalling cascades, involving action of
phosphatidylinositol 3-kinase (PI3K) and Akt (also known
as protein kinase B) [7, 13, 16, 23]. This is supported by
studies showing that overexpression of constitutively active
Akt or siRNA knockdown of PTEN (phosphatase and tensin
homolog; which both inhibit GSK3) resulted in formation of
multiple axons in culture [7]. In agreement these eﬀects were
prevented by the coexpression of constitutively active GSK3β
(Ser9Ala) indicating that the same signalling pathway was
involved [7]. Thus inactivation of GSK3 by growth factors
is a critical event in axon formation via the prevention of
phosphorylation of a number of key microtubule organising
substrates (Figure 1).
2.2. GSK3 Role in Axonal Remodelling. GSK3 activity is
also critical for the process of axonal remodelling. Axonal
remodelling occurs when an axon meets its postsynaptic
target and describes the process of decreased axonal growth,
increased axon diameter and increased growth cone size.
Axonal remodelling in mammalian neurons is controlled by
the negative regulation of GSK3 via Wingless Integration
(Wnt) proteins.
Wnts are secreted factors that initiate a downstream
signalling cascade by binding to Frizzled receptors on the
plasma membrane. The canonical Wnt signalling pathway
prevents a protein complex of axin, APC, and GSK3
from targeting β-catenin for destruction in the proteasome.
β-catenin phosphorylation by GSK3 is a key step in this
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Figure 1: GSK3 roles, substrates and signalling in immature nerve
terminals. (a) Inhibition of GSK3 activity is essential for the
establishment of axonal polarity. GSK3 activity is inhibited by
growthfactorsthatsignalthroughthePI3K/Aktsignaltransduction
cascade. When GSK3 is active, it phosphorylates both CRMP-
2 and APC, which prevents their interaction with microtubules,
arresting microtubule polymerization. When GSK3 is inhibited by
growth factors, it cannot phosphorylate CRMP-2 or APC; therefore
microtubule polymerization is stimulated. (b) Axonal remodelling
describes decreased axonal growth, increased axon diameter, and
increased growth cone size when a nascent axon meets a postsy-
naptic target. Inhibition of GSK3 increases microtubule stability to
allow axonal remodelling. GSK3 activity is inhibited by a divergent
Wnt signalling cascade. When GSK3 is active, it phosphorylates
MAP-1B; which results in increased microtubule instability. When
GSK3 is inhibited by Wnts, it cannot phosphorylate MAP-1B
therefore microtubules are stabilised.
targeting process.WhenWntbinds toFrizzled receptors,this
activates the Dishevelled protein to inhibit the function of
the “destruction complex” resulting in an inability of GSK3
to phosphorylate β-catenin. Non-phosphorylated β-catenin
then translocates to the nucleus to trigger the expression of a
number of “Wnt” genes [24].
Axonal remodelling has been studied extensively at the
mossy ﬁbre-granule cell synapse in the cerebellum [11],
where Wnt7a and Dishevelled both play a key role in
this event [8, 25, 26]. Inhibition of GSK3 activity using
the antagonist lithium mimics the eﬀect of either Wnt7a
or Dishevelled on axonal remodelling [27–29], suggestingInternational Journal of Alzheimer’s Disease 3
a key downstream role for GSK3. However a divergent
pathway to the canonical Wnt route operates in axonal
remodelling, where modulation of GSK3 activity results in
dynamicchangestothemicrotubulecytoskeletonratherthan
a l t e r a t i o n si ng e n ee x p r e s s i o n[ 11, 12].
The link between the inhibition of GSK3 activity and
changes in microtubule dynamics is the microtubule binding
proteinmicrotubule-associatedprotein-1B(MAP-1B).GSK3
phosphorylates MAP-1B both in vitro and in vivo,w h i c h
results in altered microtubule organisation and increased
microtubule instability within the axon [27, 30–32]. In
growth cones the great majority of microtubules are
dynamic, whereas on activation of the Wnt7a pathway both
stable and dynamic microtubules are present, which form
large loop-like structures [26]. This eﬀect of Wnt7a on
microtubule dynamics is mimicked by either overexpres-
sion of Dishevelled or inhibition of GSK3 [27, 29, 31].
Thus inhibition of GSK3 by a divergent Wnt signalling
pathway increases microtubule stability by decreasing MAP-
1B phosphorylation and thus allowing axonal remodelling
(Figure 1).
2.3. GSK3 Role in Synaptogenesis. After axonal remodelling
the growth cone has to diﬀerentiate into a nerve terminal.
GSK3 again has key roles in this process, via the same diver-
gent Wnt signalling pathway that controls axonal remod-
elling.Forexample,Wnt7aisakeyretrogrademessengerthat
acts to induce presynaptic maturation, as evidenced by the
clustering of vesicle proteins at nascent synaptic sites [26].
Dishevelled is also essential for this process [8]. GSK3 is part
of this maturation response too, since its inhibition mimics
the eﬀect of Wnt7a and Dishevelled on the clustering of
synaptic proteins [26, 28]. The mechanism of GSK3 action is
independent of transcription, since Wnt application caused
an increase in the size and number of synaptic sites but
not the expression of presynaptic proteins [8]. Similarly the
Wnt7a knockout mouse displays defective localisation of
presynaptic proteins but no decrease in their overall level
[8]. β-catenin is also required for SV clustering, suggesting
that its phosphorylation by GSK3 may control this event
[33, 34]. This is unlikely however, since β-catenin operates
independent of Wnt signalling in this process.
A very similar control of synaptogenesis is also observed
in Drosophila, where the ﬂy homologue of GSK3, shaggy
(Sgg), is localised presynaptically. A hypomorphic mutation
in Sgg resulted in an 80% increase in the number of boutons
(nerve terminals), an eﬀect rescued by expression of wild
type Sgg [35]. Conversely increased expression of Sgg
reduced the number of synaptic boutons below that seen
with wild type [35, 36]. Finally a large increase in bouton
number was observed when a dominant negative version of
Sgg was expressed using a presynaptic driver [35].
Sgg is a likely downstream target of the Wingless pathway,
since most components of the canonical pathway (Wingless,
Arrow,a n dDishevelled) are all expressed presynaptically
[36]. In agreement, overexpression of dominant negative
Dishevelled mimicked the reduction in bouton number
observed with Sgg overexpression. Conversely Wingless
overexpression mimicked the eﬀects of presynaptically
expressed dominant negative Sgg [36].
Interestingly an increase in microtubule loops was
observed in ﬂies with the hypomorphic mutation for Sgg
[35]. This phenotype is very similar to that observed in
mammalian axonal remodelling. In a further parallel, the
MAP-1B homolog Futsch is required for this microtubule
looping eﬀect [35]. Sgg also phosphorylates Futsch in vitro
on at least one conserved MAP-1B phosphorylation site
[37]. This suggests that inhibition of Sgg by the Wingless
signalling cascade stabilises the microtubule cytoskeleton by
preventing the phosphorylation of Futsch. Since there are
close parallels in the divergent Wnt/Wingless pathways in
both mammals and Drosophila, it suggests that inhibition of
GSK3 phosphorylation of MAP-1B may also be important
for synaptogenesis in mammals.
In summary, in the immature nerve terminal GSK3
has key roles in axonal growth, polarity, remodelling, and
diﬀerentiation. These eﬀects are controlled by a range of
diﬀerent signalling cascades and in general are mediated by
the phosphorylation-dependent control of the microtubule
cytoskeleton.
3. GSK3 Function in Mature Nerve Terminals
Until recently GSK3 was thought to have a purely devel-
opmental role in presynaptic physiology; however, recent
studies have suggested that it also performs key functions in
adult brain, speciﬁcally in neurotransmission. In agreement,
GSK3 is enriched in adult nerve terminals [8–10].
3.1.GSK3RoleinNeurotransmitterRelease. Theprimaryrole
of the nerve terminal is to release neurotransmitter, via the
fusion of SVs by exocytosis. Initial studies that examined the
roleofGSK3inneurotransmitterreleasesuggestedthatithad
no role in the process, since modulation of its activity had no
eﬀect on hippocampal neurotransmission [9, 10, 38]. Since
these studies mainly investigated the postsynaptic response
it could be argued that presynaptic eﬀects were overlooked.
However, when paired pulse facilitation (PPF) was examined
(whichisanindicatorofthemodulationofneurotransmitter
release), a lack of role for GSK3 was again apparent. For
example, there was no diﬀerence in PPF between wild type
hippocampal slices and slices obtained from transgenic
mice overexpressing GSK3β [9]. Furthermore PPF was
unaltered in hippocampal slices exposed to bath application
of GSK3 inhibitors [39]. One study has demonstrated an
indirect eﬀect of GSK3 inhibition on PPF, but this was only
revealed after inhibition of upstream PI3K [40]. In the same
study GSK3 inhibitors partially reversed an inhibition of
KCl-evoked glutamate release from synaptosomes produced
by PI3K antagonists [40]. Thus there is little evidence to date
that GSK3 plays a direct role in neurotransmitter release
from central nerve terminals.
Other studies have monitored the role of GSK3 in
SV exocytosis rather than neurotransmitter release itself.
In agreement with its lack of eﬀect on neurotransmitter
release, GSK3 antagonists had no eﬀe c to nS Ve x o c y t o s i si n4 International Journal of Alzheimer’s Disease
cultured neurons monitored using action potential-evoked
unloading of the ﬂuorescent dye FM1-43 [39]. In contrast,
overexpression of wild type GSK3β in primary hippocampal
cultures retarded FM dye unloading evoked by elevated KCl
[41]. This eﬀect was proposed to be due to GSK3-dependent
phosphorylation of an intracellular loop of a P/Q-type
voltage-dependent calcium channel (VDCC). In support,
GSK3β phosphorylated a recombinant GST-fusion protein
containingthisregioninvitroandGSK3antagonistsreversed
a phosphorylation of P/Q-type VDCCs in synaptosomes
that was evoked by inhibition of PI3K [41]. It was proposed
that GSK3 phosphorylation inhibits P/Q-type channel
activity, since overexpression of wild type GSK3β reduced
calcium inﬂux in hippocampal neurons. The lack of an
identiﬁed phosphorylation site did not allow this hypothesis
to be tested directly; however, if true it would provide a
mechanism by which the strength of neurotransmission
couldberegulatedbyGSK3phosphorylation,sinceP/Q-type
VDCCs are tightly coupled to neurotransmitter release [42].
Thus no direct role for GSK3 in neurotransmitter release
has yet been shown; however, it may indirectly regulate this
event via phosphorylation of VDCCs.
3.2. GSK3 Role in Activity-Dependent Bulk Endocytosis. In
contrast to its, as yet undetermined, role in neurotransmitter
release, GSK3 activity has a key role in SV endocytosis. Two
major endocytosis modes exist in nerve terminals to retrieve
SVs after their fusion by exocytosis. Clathrin-mediated
endocytosis (CME) retrieves single SVs with a ﬁxed rate
and is dominant during low-intensity stimulation [43, 44].
In contrast activity-dependent bulk endocytosis (ADBE)
is dominant during high-intensity stimulation [45]a n d
generateslargeendosomesdirectfromtheplasmamembrane
from which SVs can then bud [46]. Recent studies have
shown that GSK3 activity is essential for ADBE but not CME
during high-intensity stimulation and have also identiﬁed at
least one GSK3 substrate whose phosphorylation is essential
for the process.
The speciﬁc role for GSK3 in ADBE was discovered
using a battery of diﬀerent SV recycling assays in primary
neuronal culture [39]. First, uptake of large ﬂuorescent
dextran molecules (too large to be accumulated inside
single SVs) was inhibited with either GSK3 antagonists
or by silencing GSK3β expression using shRNA. Second,
pharmacological inhibition of GSK3 reduced the uptake of
smallﬂuidphasemarkersintobulkendosomesbutnotsingle
SVs. Finally, GSK3 antagonists arrested uptake of FM1-43
(which labels both ADBE and CME modes [47]) but not
FM2-10 (which only labels CME). There was an activity-
dependent requirement for GSK3 in these events, with no
role of GSK3 observed using identical assays during low-
intensity stimulation. This agrees with a selective role for
the enzyme in ADBE. One further key observation was
that acute application of GSK3 antagonists had no eﬀect
on ADBE, whereas their continual application resulted in
inhibition [39]. This indicated that GSK3 had no role
during stimulation itself but was required to phosphorylate a
substrate(s) after stimulation had terminated.
A number of endocytosis proteins are rephosphorylated
after stimulation of the nerve terminal. They are called the
dephosphins since they are co-ordinately dephosphorylated
by the calcium-dependent protein phosphatase calcineurin
on nerve terminal stimulation [48]. One of these proteins,
the large GTPase dynamin I, is phosphorylated on two major
sites on its C-terminus in resting nerve terminals (Ser-774
and Ser-778) [49]. The dephosphorylation of these sites by
calcineurin recruits the endocytosis protein syndapin I to
dynamin I [50]. The activity-dependent dephosphorylation
of dynamin I and its interaction with syndapin I and
syndapin I itself are all essential requirements for the
triggering of ADBE [51].
Since dynamin I dephosphorylation is a critical event in
the triggering of ADBE, its subsequent rephosphorylation
after stimulation is also essential for the process. Dynamin
I was originally thought to be rephosphorylated on both
major sites by cyclin-dependent kinase 5 (cdk5, see [49]).
In agreement with a key role for this rephosphorylation
event, cdk5 activity is essential for ADBE but not CME
[52]. However it was recently demonstrated that cdk5 is in
fact a priming kinase for GSK3 on dynamin I, with cdk5
phosphorylating Ser-778, allowing GSK3-dependent phos-
phorylation of Ser-774 [39]. This was shown in both in vitro
phosphorylation assays and also intact neuronal cultures
using selective cdk5 and GSK3 antagonists [39]. A direct
functional link between GSK3-dependent phosphorylation
of dynamin I to ADBE was shown by the inhibition of
dextran uptake by overexpression of dominant negative
mutants encompassing mutations at Ser-774 [39]. Thus the
rephosphorylation of Ser-774 on dynamin I by GSK3 is an
essential requirement for the maintenance of ADBE during
high-intensity stimulation. This is the ﬁrst, and to date the
only, demonstration that GSK3 activity controls SV recycling
via direct phosphorylation of the SV traﬃcking machinery.
There are eight diﬀerent dephosphin proteins, of which
at least two are also rephosphorylated by cdk5. The fact that
GSK3 acts in concert with cdk5 to phosphorylate dynamin I
suggests that these proteins may also be essential for ADBE.
These proteins are the lipid phosphatase synaptojanin and
the lipid kinase phosphatidylinositol phosphate kinase type
Iγ (PIPKIγ) which either break down or synthesise phos-
phatidylinositol (4,5) bisphosphate (PI(4,5)P2), respectively
[53, 54]. The activity of both of these enzymes is essential for
SV endocytosis [55, 56], and importantly both enzymes are
activated by their dephosphorylation by calcineurin and are
inhibited by their rephosphorylation by cdk5 [57, 58]. Scans
of the protein sequences of both synaptojanin and PIPKIγ
using bioinformatic prediction software highlight multiple
consensus sequences for GSK3 phosphorylation (S/T XXX
S/TP, where GSK3 phosphorylates the ﬁrst S/T and cdk5 the
second).Thusitiseminentlypossiblethatacdk5rephospho-
rylation event also primes these enzymes for GSK3 phospho-
rylation after high-intensity stimulation. The determination
of whether GSK3 both phosphorylates and/or regulates these
enzymes’activityisimperative,sinceatighttemporalcontrol
of lipid metabolism is essential for ADBE [59].International Journal of Alzheimer’s Disease 5
3.3. Regulation of GSK3 in Mature Nerve Terminals. GSK3
is a highly regulated kinase, with its high basal activity
negatively regulated by numerous signal transduction cas-
cades [1, 3]. Since GSK3 activity is a key requirement for
ADBE, it suggests that activation of a number of these
signal transduction cascades may also regulate ADBE. GSK3
regulation may occur in two diﬀerent instances, either acute
control driven by action potential ﬁring or longer-term
control driven by activation of signalling cascades by growth
factors/hormones.
Depolarization of neurons by prolonged stimulation
results in GSK3 phosphorylation and thus its inactivation
[60, 61]. This suggests that GSK3 activity could be acutely
regulated during transient depolarization by action potential
stimulation. This is indeed the case, with phosphorylation
of GSK3 being triggered during intense, but not mild action
potential stimulation in primary neuronal cultures (Smillie
unpublished). Interestingly dynamin I is only dephospho-
rylated by calcineurin during high-, but not low-intensity
stimulation[51].ThuswhendynaminIandthedephosphins
are being dephosphorylated by calcineurin, GSK3 is simulta-
neously inactivated allowing maximal dephosphorylation to
occur.
There are a number of possible candidates for the protein
kinase that mediates the acute activity-dependent phos-
phorylation of GSK3. For example, the calcium-dependent
proteinkinaseCaMKIIphosphorylatesGSK3duringchronic
depolarization [62]. Also the activity of Akt is increased
by prolonged membrane depolarization [63–65], suggesting
that it may also phosphorylate GSK3 under these conditions.
Preliminary ﬁndings from our laboratory suggest that Akt
may be the activity-dependent GSK3 kinase, since Akt
activation only occurred during intense, but not mild, neu-
ronal stimulation (Smillie, unpublished). Thus an activity-
dependent signal transduction cascade may activate Akt to
inhibit GSK3 in nerve terminals, aiding the triggering of
ADBE (Figure 2). The identity of the upstream components
of this cascade will be of great interest and is currently under
investigation.
GSK3 activity in mature nerve terminals can also be
controlled in the longer term by classical signalling cascades.
To date there are three major pathways identiﬁed which
converge on GSK3 and all result in its phosphorylation
and inhibition. Amino acids signal through the mTOR/S6K
pathway, insulin and growth factors signal via a PI3K/Akt
pathway, and growth factors also act through activation
of MAPK and MAPKAP-K1 [1]. Considering the key role
for GSK3 in ADBE, longer-term inhibition by any of these
cascades should greatly reduce the functionality of this SV
endocytosis mode (Figure 2). In agreement, overexpression
of a constitutively active form of Akt results in the arrest
of ADBE but not CME in primary neuronal cultures
(Smille unpublished). It will be of great interest to identify
the ligands that trigger these signal transduction cascades
to determine how they control both GSK3 activity and
modulate ADBE.
The converse of regulated inhibition of GSK3 via its
phosphorylation is its activation by its dephosphorylation
[1]. This will be critical for the activity-dependent inhibition
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Figure 2: GSK3-dependent control of SV recycling in mature nerve
terminals. When GSK3 is active, it phosphorylates Ser774 on
dynamin I, which inhibits the interaction between dynamin I and
syndapinI.Thisinteractionisessentialforthetriggeringofactivity-
dependentbulkendocytosis(ADBE)andthusduringhigh-intensity
stimulation GSK3 is inhibited in an activity-dependent manner by
Akt (action potential symbol). After stimulation, GSK3 is active
and can rephosphorylate dynamin I. If the rephosphorylation of
dynamin I by GSK3 is inhibited, the subsequent cycle of ADBE
is arrested. Signal transduction cascades that may regulate GSK3
activity in the longer term are: a mammalian target of rapamycin
(mTOR)/S6 kinase pathway (activated by amino acids), a PI3K/Akt
pathway (activated by either insulin or growth factors), or a
mitogen-activated protein kinase (MAPK)/MAPKAP-K1 pathway
(activated by growth factors). GSK3 has no role in clathrin-
mediated endocytosis (CME). GSK3 may perform an additional
role in SV recycling by negatively regulating neurotransmitter
release (dotted line). This is because GSK3 is proposed to phospho-
rylate P/Q-type calcium channels and inhibit calcium inﬂux into
the nerve terminal.
of GSK3, since it must then be rapidly dephosphorylated
after stimulation to rephosphorylate dynamin I. GSK3 can
be dephosphorylated by either PP1 or PP2A protein phos-
phatases [66]. In agreement, the PP1 and PP2A antagonist
okadaic acid increases the basal phosphorylation of GSK3
in both hippocampal slices and primary neuronal cultures
[10, 67]. Another possible level of complexity has recently
been reported with possible diﬀerential dephosphorylation
of GSK3α and GSK3β by PP2A and PP1, respectively [68].
In ADBE, GSK3 acts in concert with the calcium-
dependent protein phosphatase calcineurin. Interestingly
these two enzymes are related on a number of diﬀerent func-
tionallevels.Forexample,calcineurinactivitycanbearrested
by an endogenous inhibitor called regulator of calcineurin 1
(RCAN1) [69]. Both RCAN1 activity and its degradation are
regulated by GSK3-dependent phosphorylation [70–72]. In
addition, RCAN1 activity also increases expression of GSK3
[73]. Thus the function and regulation of both calcineurin
and GSK3 are tightly controlled by a number of intricate
feedback pathways, highlighting the key roles their activities
play in nerve terminal function. Thus control of GSK36 International Journal of Alzheimer’s Disease
dephosphorylation, and indeed the control of calcineurin by
GSK3, may be critical for the rephosphorylation of dynamin
I and control ADBE in nerve terminals.
In summary GSK3 has one recently identiﬁed key role
in the function of the mature nerve terminal, an essential
requirement in ADBE. It remains to be seen whether this is
its only role in the SV life cycle or whether this is the ﬁrst of
many to be revealed.
4.PresynapticFunctionof GSK3 in
Alzheimer’sDisease
As discussed above, GSK3 activity plays key roles in shaping
nerve terminal development and function. Thus regulation
of its activity may provide a mechanism to increase synaptic
function, especially in neurodegenerative disorders such as
Alzheimer’s disease. In Alzheimer’s disease, synapse loss
often precedes neuronal death [74], therefore modulation of
the key identiﬁed roles of GSK3 in synaptogenesis oﬀers the
possibility of either generating new synaptic contacts or at
least stabilising existing synapses before irreversible neuronal
loss occurs.
Similarly, synaptic failure is one of the ﬁrst events
observed in patients with mild cognitive impairment, a pro-
dromal state of Alzheimer’s disease [74]; The essential role
for GSK3 in ADBE suggests that its modulation may impact
on neurotransmission during periods of intense neuronal
activity such as during learning and memory generation. In
agreement, inhibition of GSK3 results in increased neuro-
transmission during high-intensity stimulation [39]. Thus
modulation of presynaptic GSK3 activity may either increase
synaptic function or at least slow synaptic failure. This is
especially interesting since GSK3 activity can be regulated
by a wide variety of signal transduction cascades, providing
possible entry points forpharmacologicalintervention inthe
disease.
In summary, the past 10 years of research have revealed
that GSK3 is a key integrator of presynaptic signalling whose
output determines the strength of neurotransmission via
synaptic remodelling, synaptic strength, or synaptic capacity.
The next 10 years will determine whether modulation of any
of these key functional roles will facilitate the treatment of
neurodegenerative disorders such as Alzheimer’s disease.
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